Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-407-2718516
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees31
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable
Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions
What is Hemispherx BioPharma's stock symbol?
Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."
When did Hemispherx BioPharma's stock split? How did Hemispherx BioPharma's stock split work?
Shares of Hemispherx BioPharma reverse split on the morning of Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of Hemispherx BioPharma stock prior to the reverse split would have 2 shares after the split.
How were Hemispherx BioPharma's earnings last quarter?
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) announced its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter. View Hemispherx BioPharma's Earnings History.
When is Hemispherx BioPharma's next earnings date?
What price target have analysts set for HEB?
2 equities research analysts have issued 12 month price objectives for Hemispherx BioPharma's shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Hemispherx BioPharma's stock price to reach $7.00 in the next year. This suggests a possible upside of 257.1% from the stock's current price. View Analyst Price Targets for Hemispherx BioPharma.
What is the consensus analysts' recommendation for Hemispherx BioPharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hemispherx BioPharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hemispherx BioPharma.
Has Hemispherx BioPharma been receiving favorable news coverage?
Media stories about HEB stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hemispherx BioPharma earned a news impact score of -1.3 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Hemispherx BioPharma.
Are investors shorting Hemispherx BioPharma?
Hemispherx BioPharma saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 120,600 shares, a decline of 9.5% from the July 31st total of 133,200 shares. Based on an average trading volume of 170,700 shares, the short-interest ratio is presently 0.7 days. Approximately 5.2% of the shares of the company are short sold. View Hemispherx BioPharma's Current Options Chain.
Who are some of Hemispherx BioPharma's key competitors?
Some companies that are related to Hemispherx BioPharma include Devonian Health Group (GSD), Regeneus (RGS), Cellmid (CDY), Skinbiotherapeutics (SBTX), BTC Health (BTC), Adalta (1AD), Destiny Pharma (DEST), NovaBay Pharmaceuticals (NBY), biOasis Technologies (BTI), ImmuPharma (IMM), Collagen Solutions (COS), Suda Pharmaceuticals (SUD), Ibio (IBIO), Fusion Antibodies (FAB) and Trillium Therapeutics (TRIL).
What other stocks do shareholders of Hemispherx BioPharma own?
Who are Hemispherx BioPharma's key executives?
Hemispherx BioPharma's management team includes the folowing people:
- Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 66)
- Mr. Adam Pascale, Chief Financial Officer (Age 71)
- Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 68)
- Mr. Wayne S. Springate, Sr. VP of Operations (Age 48)
- Ms. Ellen Lintal, Chief Accounting Officer
Who are Hemispherx BioPharma's major shareholders?
Hemispherx BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.47%) and A.R.T. Advisors LLC (0.45%). Company insiders that own Hemispherx BioPharma stock include Stewart Appelrouth, Thomas K Equels, Wayne S Springate and William M Mitchell. View Institutional Ownership Trends for Hemispherx BioPharma.
Which institutional investors are selling Hemispherx BioPharma stock?
Which institutional investors are buying Hemispherx BioPharma stock?
HEB stock was purchased by a variety of institutional investors in the last quarter, including A.R.T. Advisors LLC. Company insiders that have bought Hemispherx BioPharma stock in the last two years include Stewart Appelrouth, Thomas K Equels, Wayne S Springate and William M Mitchell. View Insider Buying and Selling for Hemispherx BioPharma.
How do I buy shares of Hemispherx BioPharma?
Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Hemispherx BioPharma's stock price today?
One share of HEB stock can currently be purchased for approximately $1.96.
How big of a company is Hemispherx BioPharma?
What is Hemispherx BioPharma's official website?
How can I contact Hemispherx BioPharma?
Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.
MarketBeat Community Rating for Hemispherx BioPharma (NYSEAMERICAN HEB)
MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe HEB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days.
